Cargando…

Chapter 1 The need for chemotherapy and prophylaxis against viral diseases

The chapter discusses the need for chemotherapy and prophylaxis against viral diseases. It briefly mentions clinical diseases and syndromes such as influenza, respiratory tract infections, hepatitis, and arbovirus infections resulting from virus infections. Viruses causing respiratory diseases, as w...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier B.V. 1985
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7134146/
https://www.ncbi.nlm.nih.gov/pubmed/32287577
http://dx.doi.org/10.1016/S0168-7069(08)70009-0
_version_ 1783517776669835264
collection PubMed
description The chapter discusses the need for chemotherapy and prophylaxis against viral diseases. It briefly mentions clinical diseases and syndromes such as influenza, respiratory tract infections, hepatitis, and arbovirus infections resulting from virus infections. Viruses causing respiratory diseases, as well as many other diseases in humans are also discussed in the chapter. It describes the vaccines that are used to check the attack of different viruses as well as their cost-effectiveness. There is a list of some viruses that have been ranked according to different variables in an attempt to select a good candidate for an antiviral drug. The incidence of the viral disease is naturally an important factor, as is the severity of the disease. The incidence can be obtained for diseases being reported in accordance with local regulations, but in many cases viral diseases are not reported and the incidence has to be calculated from different surveys. Also, a grading of the severity is not easy and an example is when herpesvirus infections are handled as a group, which includes both herpes encephalitis and cold sores. The greatest challenges and probably the most difficult and medically important areas for prophylaxis and therapy of viral diseases are the viruses that are rapidly changing in antigenic composition and/or viruses with animal reservoirs (influenza and arboviruses) and those forming latent infections (herpesviruses).
format Online
Article
Text
id pubmed-7134146
institution National Center for Biotechnology Information
language English
publishDate 1985
publisher Published by Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-71341462020-04-08 Chapter 1 The need for chemotherapy and prophylaxis against viral diseases Perspect Med Virol Article The chapter discusses the need for chemotherapy and prophylaxis against viral diseases. It briefly mentions clinical diseases and syndromes such as influenza, respiratory tract infections, hepatitis, and arbovirus infections resulting from virus infections. Viruses causing respiratory diseases, as well as many other diseases in humans are also discussed in the chapter. It describes the vaccines that are used to check the attack of different viruses as well as their cost-effectiveness. There is a list of some viruses that have been ranked according to different variables in an attempt to select a good candidate for an antiviral drug. The incidence of the viral disease is naturally an important factor, as is the severity of the disease. The incidence can be obtained for diseases being reported in accordance with local regulations, but in many cases viral diseases are not reported and the incidence has to be calculated from different surveys. Also, a grading of the severity is not easy and an example is when herpesvirus infections are handled as a group, which includes both herpes encephalitis and cold sores. The greatest challenges and probably the most difficult and medically important areas for prophylaxis and therapy of viral diseases are the viruses that are rapidly changing in antigenic composition and/or viruses with animal reservoirs (influenza and arboviruses) and those forming latent infections (herpesviruses). Published by Elsevier B.V. 1985 2008-05-29 /pmc/articles/PMC7134146/ /pubmed/32287577 http://dx.doi.org/10.1016/S0168-7069(08)70009-0 Text en © 1985 Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Chapter 1 The need for chemotherapy and prophylaxis against viral diseases
title Chapter 1 The need for chemotherapy and prophylaxis against viral diseases
title_full Chapter 1 The need for chemotherapy and prophylaxis against viral diseases
title_fullStr Chapter 1 The need for chemotherapy and prophylaxis against viral diseases
title_full_unstemmed Chapter 1 The need for chemotherapy and prophylaxis against viral diseases
title_short Chapter 1 The need for chemotherapy and prophylaxis against viral diseases
title_sort chapter 1 the need for chemotherapy and prophylaxis against viral diseases
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7134146/
https://www.ncbi.nlm.nih.gov/pubmed/32287577
http://dx.doi.org/10.1016/S0168-7069(08)70009-0